A Unique Drug Delivery Technology for MM
Brea C. Lipe, MD describes the unique treatment technology explored in the PERSEUS phase three trial.
Summary
This segment focuses on a large, 700+ patient randomized phase three trial conducted by the European Myeloma Network comparing a quadruplet drug regimen (lenalidomide, bortezomib, dexamethasone, and subcutaneous daratumumab) to a triplet regimen without daratumumab for multiple myeloma. The quadruplet regimen demonstrated improved progression-free and overall survival compared to the triplet. The use of subcutaneous daratumumab makes the regimen more convenient for patients than prior intravenous regimens. While efficacy and safety are most important, convenience is a consideration for many patients in terms of quality of life and logistics. This trial provides evidence that this quadruplet regimen is effective and more convenient for patients.
Summary was AI-generated and edited for clarity.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
